Related Experiment Video
Updated: Jul 17, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia
1Royal Prince Alfred Hospital, RPA Newborn Care, Missenden Road, Camperdown, New South Wales, Australia, 2050. david.osborn@email.cs.nsw.gov.au
Insights
Thyroid hormone therapy for preterm infants with transient hypothyroxinaemia shows insufficient evidence for improving neonatal outcomes or neurodevelopment. Further research is needed to determine its effectiveness and safety in this vulnerable population.
Area of Science:
- Neonatal Medicine
- Endocrinology
- Developmental Pediatrics
Background:
- Extremely premature infants often experience transient hypothyroxinaemia (low thyroid hormone levels) in early life.
- This condition is linked to increased neonatal morbidity, mortality, and long-term developmental issues.
- Thyroid hormone therapy is being explored as a potential intervention to mitigate these risks.
Purpose of the Study:
- To evaluate the efficacy of thyroid hormone therapy in preterm infants diagnosed with transient hypothyroxinaemia.
- To assess the impact of this therapy on neonatal outcomes and neurodevelopmental trajectories.
- To determine if thyroid hormone supplementation can prevent adverse effects associated with low thyroid hormone levels in preterm neonates.
Main Methods:
- A comprehensive literature search was conducted across multiple databases, including CENTRAL, MEDLINE, EMBASE, and conference proceedings.
- Eligible trials included preterm infants with transient hypothyroxinaemia (low thyroid hormone, normal TSH) randomly assigned to thyroid hormone therapy or a control group (placebo/no treatment).
- Data were extracted and analyzed using standard Cochrane Collaboration methods, calculating relative risks and weighted mean differences.
Main Results:
- Only one eligible study, involving 23 infants, was identified.
- The study found no significant differences in neonatal mortality, bronchopulmonary dysplasia, or other major morbidities between thyroxine and placebo groups.
- No significant differences in growth parameters or thyroid hormone levels were observed, and neurodevelopmental follow-up was inadequate.
Conclusions:
- There is insufficient evidence to support the use of thyroid hormones for treating transient hypothyroxinaemia in preterm infants.
- The current evidence does not demonstrate improvements in neonatal morbidity and mortality or reductions in neurodevelopmental impairments.
- Further rigorous research is necessary to establish the role and safety of thyroid hormone therapy in this population.
Background:
Extremely premature infants are at risk of transient hypothyroxinaemia in the first weeks after birth. These low thyroid hormone levels are associated with an increased incidence of neonatal morbidity, mortality and longer term developmental impairments. Thyroid hormone therapy might prevent these problems.
Objectives:
To determine the evidence for thyroid hormone therapy in preterm infants with transient hypothyroxinaemia (low thyroid hormone level, normal TSH) for improvement of neonatal outcomes and neurodevelopment.
Search Strategy:
Searches were performed of The Cochrane Central Register of Controlled (CENTRAL, The Cochrane Library, Issue 1, 2006), MEDLINE (1966 - March 2006), PREMEDLINE (March 2006), EMBASE (1980 - March 2006), previous reviews including cross references, abstracts and conference proceedings, supplemented by requests to expert informants.
Selection Criteria:
Trials enrolling preterm infants with transient hypothyroxinaemia (low thyroid hormone level, normal TSH level) in the neonatal period, using random or quasi-random patient allocation to thyroid hormone therapy compared to control (placebo or no treatment).
Data Collection And Analysis:
Independent assessment of trial quality and data extraction by each review author. Synthesis of data using relative risk (RR) and weighted mean difference (WMD) using standard methods of the Cochrane Collaboration and its Neonatal Review Group.
Main Results:
Only one study was eligible. Chowdhry (1984) enrolled 23 infants < 1250 g and 25 - 28 weeks gestation with transient hypothyroxinaemia (serum total T4 =4 mug/dl and TSH = 20 IU/L). Infants were randomised to thyroxine 10 mug/kg/day or placebo beginning on day 15 and continuing daily for seven weeks. Chowdhry (1984) reported no neonatal mortality and one infant death in each group prior to discharge. No significant difference was reported in CLD at 28 days or 36 weeks, patent ductus arteriosus, necrotising enterocolitis, retinopathy or prematurity, weight gain, growth in head circumference or length. No significant difference was reported for mean T4 levels between thyroxine and placebo treated infants on day 21, 35, 49, 63 and 77 after birth. Free T4 was not measured. Neurodevelopmental follow up was inadequate to draw any conclusions from.
Authors' Conclusions:
There is insufficient evidence to determine whether use of thyroid hormones for treatment of preterm infants with transient hypothyroxinaemia results in changes in neonatal morbidity and mortality, or reductions in neurodevelopmental impairments. Further research is required.
Related Concept Videos
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hypothyroidism II: Pathophysiology
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Hyperthyroidism I: Introduction
Hyperthyroidism II: Pathophysiology
Graves Disease II: Pathophysiology